Market cap
₹1,105 Cr
Recently Viewed
Clear AllNSE: BAJAJHCARE | BSE: 539872
₹327.85
₹6.10
(1.90%)
As on 04-May-2026IST
Market cap
₹1,105 Cr
Revenue (TTM)
₹612 Cr
P/E Ratio
21.1
P/B Ratio
2.2
Div. Yield
0.3 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹50 Cr
ROE
11.8 %
ROCE
11.4 %
Industry P/E
36.61
EV/EBITDA
11.8
Debt to Equity
0.5
Book Value
₹170.2
EPS
₹16.6
Face value
5
Shares outstanding
33,662,661
CFO
₹245.58 Cr
EBITDA
₹716.94 Cr
Net Profit
₹319.39 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bajaj Healthcare
| -21.0 | 5.4 | -7.4 | -36.5 | 1.5 | -- | -- |
|
BSE Healthcare
| 4.2 | 9.4 | 7.1 | 7.8 | 25.2 | 13.8 | 11.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Bajaj Healthcare
| -34.3 | 52.2 | -15.4 | 7.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bajaj Healthcare
|
327.9 | 1,105.0 | 612.5 | 49.8 | 10.8 | 11 | 21.1 | 2.2 |
| 1,069.2 | 13,106.4 | 2,512.3 | 543.7 | 28.3 | 19.3 | 24.1 | 4.1 | |
| 475.9 | 8,263.0 | 1,053.1 | 293.6 | 32.3 | 24.6 | 28.1 | 6.4 | |
| 1,195.2 | 12,502.7 | 1,158.7 | 309.6 | 31.9 | 17.3 | 40 | 6.6 | |
| 1,793.2 | 33,844.6 | 8,850.1 | 894.8 | 15.2 | 19.8 | 38.9 | 6.8 | |
| 372.3 | 4,063.9 | 159.3 | 47.8 | 39.0 | 18.6 | 85 | 14.7 | |
| 16,124.0 | 20,702.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 115.6 | 12.5 | |
| 2,417.0 | 4,008.7 | 707.5 | 115.2 | 17.8 | 19.4 | 34.8 | -- | |
| 894.3 | 4,111.0 | 588.5 | 102.9 | 22.1 | 12.7 | 40.5 | 4.9 | |
| 212.4 | 5,610.7 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.4 |
No Review & Analysis are available.
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in... India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 " amino " 1 " adamantanol, N " boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India. Read more
Incorporated
1993
Chairman
Sajankumar Rameshwarlal Bajaj
Managing Director
Sajankumar Rameshwarlal Bajaj
Headquarters
Thane Dist, Maharashtra
Website
Looking for more details about Bajaj Healthcare Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Bajaj Healthcare Ltd is ₹327.85 (NSE) and ₹328.25 (BSE) as of 04-May-2026 IST. Bajaj Healthcare Ltd has given a return of 1.51% in the last 3 years.
The P/E ratio of Bajaj Healthcare Ltd is 21.12 times as on 04-May-2026, a 42 discount to its peers’ median range of 36.61 times.
The P/B ratio of Bajaj Healthcare Ltd is 2.19 times as on 04-May-2026, a 9 discount to its peers’ median range of 2.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
49.42
|
4.73
|
|
2024
|
0.00
|
2.90
|
|
2023
|
13.24
|
2.29
|
|
2022
|
13.16
|
2.86
|
|
2021
|
3.92
|
2.52
|
The 52-week high and low of Bajaj Healthcare Ltd are Rs 608.90 and Rs 273.25 as of 04-May-2026.
Bajaj Healthcare Ltd has a market capitalisation of ₹ 1,105 Cr as on 04-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bajaj Healthcare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.